When alliances fail, is arbitration the answer?

The COVID-19 global pandemic has seen alliances between pharmaceuticals giants and, on the one hand, universities (Oxford University and AstraZeneca) and, on the other, small, family-owned biotechnology companies (BioNTech and Pfizer) to develop vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?

Pfizer infringed haemophilia therapy patent, says court

Apple wins just $250 in Masimo smartwatch clash

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

When alliances fail, is arbitration the answer?

Editor's picks

Editor's picks

More features